Clinical Trial Details
GOG 3001/ Amgen TRINOVA-3 Official Title:
GOG 3001/ Amgen TRINOVA-3 - A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
Start Date September 27, 2013
End Date November 1, 2018
| Gender Preference |
|Female|| Age Group |
|18 - 99 years|
| Principal Investigator |
|David Bender, MD|
| Contact Info |
Sharon Stockman, (319) 356-2015
Participants in this study are women with advanced epithelial ovarian, primary peritoneal, or fallopian tube cancers who are receiving initial treatment. The purpose of this study is to see if participants who are treated with paclitaxel and carboplatin (chemotherapy drugs) plus AMG 386, followed by 18 months of AMG 386 continued after the chemotherapy, will have an improved outcome compared to participants treated with paclitaxel and carboplatin plus AMG 386 placebo, followed by 18 months of AMG 386 placebo after the chemotherapy.
Approximately 2000 women are expected to participate in this study at up to 300 sites around the world. Approximately 10 subjects from the University of Iowa may participate in the study.
|201209506 ; Bender ; cancer ; epithelial ovarian cancer ; fallopian tube cancer ; Phase three ; primary peritoneal cancer ; |